Tepezza (teprotumumab-trbw) Receives FDA Approval
Jan. 21, 2020BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.
Your regular online holiday shopping can help the GDATF fund its patient education and support programs! By purchasing through one of the following channels, online retailers will donate a portion of proceeds to the Graves’ Disease & Thyroid Foundation - at no cost to you!
